Janssen Research & Development, Llc

This study tests a new drug, JNJ-78934804, against an existing treatment (guselkumab) in 644 people with moderate to severe ulcerative colitis, a chronic condition causing colon inflammation and ulcers. The goal is to see if the new drug can safely bring about remission (no sympt…

This study tests whether giving a single dose of tocilizumab before the cancer drug ramantamig can prevent or reduce cytokine release syndrome (CRS), a serious flu-like reaction, in people with relapsed or refractory multiple myeloma. About 230 participants will receive either to…

This study tests whether giving a combination of drugs (amivantamab plus lazertinib or chemotherapy) before surgery can shrink or stop the growth of a specific type of lung cancer (EGFR-mutated non-small cell lung cancer). About 68 people with stage II to IIIB cancer that can be …

This study tests a new drug, JNJ-79635322, against another drug, teclistamab, in people whose multiple myeloma has returned or stopped responding after 1 to 3 prior treatments. About 700 adults will be randomly assigned to one of the two drugs. The goal is to see which one works …

This study tests a new drug, JNJ-78934804, against another drug (guselkumab) in 460 people with moderate to severe Crohn's disease. The goal is to see if it can reduce symptoms and heal the gut lining after 48 weeks. Participants must have had Crohn's for at least 12 weeks and ha…

This study will follow about 100 adults in Saudi Arabia who have moderate to severe Crohn's disease or ulcerative colitis and are starting guselkumab. Researchers want to see how long patients keep taking the medicine without stopping. The study does not give any treatment—it jus…

This early-stage study tests a new drug called JNJ-95804306 in about 280 people with blood cancers (like leukemia) that have returned or not improved after standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. The stud…